---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-122815"
form_type: "8-K"
ticker: "PEPG"
cik: "0001835597"
company_name: "PepGen Inc."
filed_at: "2024-11-07T23:59:59+00:00"
generated_at: "2026-05-30T03:49:07.825900+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# PepGen Q3 net loss $21.4M; cash $138.9M; DM1/DMD trial updates expected 2025

## Summary
- Net loss of $21.4M ($0.66 per share) vs $23.3M ($0.98) in Q3 2023.
- Cash and equivalents of $138.9M as of Sept 30, 2024, funding operations into 2026.
- R&D expense $17.7M (down 14% YoY); G&A $5.4M (up 29% YoY).
- FREEDOM-DM1 5 & 10 mg/kg data expected Q1 2025; 15 mg/kg cohort in H2 2025.
- Appointed Paul Streck, MD, MBA, as EVP and Head of R&D in August 2024.

## SEC filing metadata
- accession: 0000950170-24-122815
- form_type: 8-K
- ticker: PEPG
- cik: 0001835597
- company_name: PepGen Inc.
- filed_at: 2024-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1835597/000095017024122815/0000950170-24-122815-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1835597/000095017024122815/pepg-20241107.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-122815
- JSON: https://secwatch.observer/filing/0000950170-24-122815.json
- Plain text: https://secwatch.observer/filing/0000950170-24-122815.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.